title: Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
abstract: We aimed to clarify the association between a novel serum fibrosis marker,Wisteria floribundaagglutinin-positive Mac-2-binding protein (WFA⁺-M2BP), and hepatocellular carcinoma (HCC) development in 355 patients with chronic hepatitis C who achieved sustained virologic response (SVR) through interferon-based antiviral therapy. Pretreatment serum WFA⁺-M2BP levels were quantified and the hazard ratios (HRs) for HCC development were retrospectively analyzed by Cox proportional hazard analysis. During the median follow-up time of 2.9 years, 12 patients developed HCC. Multivariate analysis demonstrated that high serum WFA⁺-M2BP (≥2.80 cut off index (COI), HR = 15.20,p= 0.013) and high fibrosis-4 (FIB-4) index (≥3.7, HR = 5.62,p= 0.034) were independent risk factors for HCC development. The three- and five-year cumulative incidence of HCC in patients with low WFA⁺-M2BP were 0.4% and 0.4%, respectively, whereas those of patients with high WFA⁺-M2BP were 7.7% and 17.6%, respectively (p< 0.001). In addition, combination of serum WFA⁺-M2BP and FIB-4 indices successfully stratified the risk of HCC: the five-year cumulative incidences of HCC were 26.9%, 6.8%, and 0.0% in patients with both, either, and none of these risk factors, respectively (p< 0.001). In conclusion, pretreatment serum WFA⁺-M2BP level is a useful predictor for HCC development after achieving SVR.
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. syusato@juntendo.ac.jp.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Sato
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. genda@rice.ocn.ne.jp.
authors.forename: Takuya
authors.initials: T
authors.lastname: Genda
authors.affiliation: Department of Hepatology, East Shonan General Hospital, Kanagawa 253-0083, Japan. takafumi@air.ocn.ne.jp.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ichida
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. n-amano@juntendo.ac.jp.
authors.forename: Nozomi
authors.initials: N
authors.lastname: Amano
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. sho-sato@juntendo.ac.jp.
authors.forename: Sho
authors.initials: S
authors.lastname: Sato
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. perseverance3@hotmail.co.jp.
authors.forename: Ayato
authors.initials: A
authors.lastname: Murata
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. htudura@juntendo.ac.jp.
authors.forename: Hironori
authors.initials: H
authors.lastname: Tsuzura
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. ynarita@juntendo.ac.jp.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Narita
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. yoshio-k.s52@live.jp.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kanemitsu
authors.affiliation: Department of Hepatology, East Shonan General Hospital, Kanagawa 253-0083, Japan. khirano-tym@umin.ac.jp.
authors.forename: Katsuharu
authors.initials: K
authors.lastname: Hirano
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. yshimada@juntendo.ac.jp.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shimada
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. katsu0716@shore.ocn.ne.jp.
authors.forename: Katsuyori
authors.initials: K
authors.lastname: Iijima
authors.affiliation: Department of Pathology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. mdksmrwjunten522@ybb.ne.jp.
authors.forename: Ryo
authors.initials: R
authors.lastname: Wada
authors.affiliation: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka 410-2295, Japan. nagahara@juntendo.ac.jp.
authors.forename: Akihito
authors.initials: A
authors.lastname: Nagahara
authors.affiliation: Department of Gastroenterology, Juntendo University School of Medicine, Tokyo 113-8431, Japan. sumio@juntendo.ac.jp.
authors.forename: Sumio
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood* / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood* / Q000378:metabolism*; D008875:Middle Aged; D037121:Plant Lectins / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011485:Protein Binding / Q000502:physiology; D034781:Receptors, N-Acetylglucosamine / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D016898:Interferon-alpha; D008562:Membrane Glycoproteins; D037121:Plant Lectins; D034781:Receptors, N-Acetylglucosamine; D011994:Recombinant Proteins; C114782:TAA90K protein, human; C040129:wisteria lectin; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: WFA+-M2BP; chronic hepatitis C; hepatocellular carcinoma; risk factor; sustained virological response